Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

January 22, 2025

Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications

Xindi Ke, Shangze Jiang, Qiaoxin Wei, et al.

Clin Mol Hepatol. 2025;31(3):685-705.

The role of the gut microbiome in the development and progression of liver cancer has long been recognized. However, the presence of microbes in tumors that were previously considered sterile...

Review

February 5, 2025

Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications

Huihai Yang, Martina Mang Leng Lei, Longfei Xie, et al.

Clin Mol Hepatol. 2025;31(3):706-729.

Hepatocellular carcinoma (HCC) is a highly lethal cancer due to its aggressive nature and poor prognosis. Adenosine, a key metabolic regulator in the tumor microenvironment (TME), plays a crucial role...

Review

March 26, 2025

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum

Vishnu Girish, Rakhi Maiwall

Clin Mol Hepatol. 2025;31(3):730-752.

Kidney disease in cirrhosis is now viewed as a continuum encompassing acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD), rather than three different disorders. Contemporary...

Review

April 2, 2025

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

Hee Yeon Kim, Mary E. Rinella

Clin Mol Hepatol. 2025;31(3):753-770.

Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for...

Review

April 16, 2025

Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease

Eiji Kakazu, Masaaki Mino, Tatsuya Kanto

Clin Mol Hepatol. 2025;31(3):771-795.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its relatively advanced form, metabolic dysfunction-associated steatohepatitis (MASH), are becoming increasingly prevalent worldwide, making their prevention and management an urgent global health priority....

Original Article

January 6, 2025

High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease

Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, et al.

Clin Mol Hepatol. 2025;31(3):796-809.

Background/Aims: There are no hepatocellular carcinoma (HCC) surveillance recommendations for non-viral chronic liver diseases (CLD), such as metabolic dysfunction-associated steatotic liver disease (MASLD). We explored the Steatosis-Associated Fibrosis Estimator (SAFE)...

Original Article

January 17, 2025

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial

Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, et al.

Clin Mol Hepatol. 2025;31(3):810-822.

Background/Aims: Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral...

Original Article

January 22, 2025

Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis

Jae Yeon Kim, Hyeri Park, Soo Young Park, et al.

Clin Mol Hepatol. 2025;31(3):823-840.

Background/Aims: Epithelial-to-mesenchymal transition (EMT) plays a crucial role in hepatic fibrogenesis and liver repair in chronic liver disease. Our research highlights the antifibrotic potential of placenta-derived mesenchymal stem cells (PD-MSCs)...

Original Article

February 5, 2025

Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome

Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, et al.

Clin Mol Hepatol. 2025;31(3):841-865.

Background/Aims: Hepatitis B virus (HBV) hijacks host cell metabolism, especially host glutamine metabolism, to support its replication. Glutamate dehydrogenase 1 (GDH1), a mitochondrial enzyme crucial for glutamine metabolism, can interact...

Original Article

February 5, 2025

Baveno VI-SSM stratifies the risk of portal hypertensionrelated events in patients with HBV-related cirrhosis

Haiyu Wang, Weihao Liang, Ling Zhou, et al.

Clin Mol Hepatol. 2025;31(3):866-880.

Background/Aims: Cirrhotic patients with liver stiffness measurement (LSM)

Original Article

February 5, 2025

Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study

Bingtian Dong, Ruiling He, Shenghong Ju, et al.

Clin Mol Hepatol. 2025;31(3):881-898.

Background/Aims: A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop...

Original Article

February 5, 2025

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study

Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.

Clin Mol Hepatol. 2025;31(3):899-913.

Background/Aims: The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C,...

Original Article

February 6, 2025

GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma

Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, et al.

Clin Mol Hepatol. 2025;31(3):914-934.

Background/Aims: Hepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC...

Original Article

February 10, 2025

Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target

Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, et al.

Clin Mol Hepatol. 2025;31(3):935-959.

Background/Aims: Identifying patients with intrahepatic cholangiocarcinoma (ICC) likely to benefit from immunochemotherapy, the new front-line treatment, remains challenging. We aimed to unveil a novel radiotranscriptomic signature that can facilitate treatment...

Original Article

March 4, 2025

CD36 promotes iron accumulation and dysfunction in CD8⁺ T cells via the p38-CEBPB-TfR1 axis in earlystage hepatocellular carcinoma

Yifei Qin, Fei Huo, Zhuan Feng, et al.

Clin Mol Hepatol. 2025;31(3):960-980.

Background/Aims: The identification of factors that lead to CD8+ T cell dysfunction within the tumor microenvironment (TME) holds great promise for the development of innovative immunotherapies. However, the mechanisms underlying...

Original Article

March 11, 2025

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway

Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, et al.

Clin Mol Hepatol. 2025;31(3):981-1002.

Background/Aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in...

Original Article

March 17, 2025

Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues

Rui Huang, Dae Won Jun, Hidenori Toyoda, et al.

Clin Mol Hepatol. 2025;31(3):1003-1017.

Background/Aims: Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment. Methods: We analyzed...

Original Article

April 4, 2025

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease

Hye Won Lee, Jae Seung Lee, Mi Na Kim, et al.

Clin Mol Hepatol. 2025;31(3):1018-1031.

Background/Aims: Recently, the Korean Association for the Study of the Liver (KASL) introduced a noninvasive test-based approach that uses the fibrosis-4 (FIB-4) index followed by vibration-controlled transient elastography (VCTE) to...

Original Article

April 11, 2025

MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation

Tiantian Wang, Dean Rao, Chenan Fu, et al.

Clin Mol Hepatol. 2025;31(3):1032-1057.

Background/Aims: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, and abnormal MET expression plays a crucial role in its progression. However, the specific pathogenic mechanisms of MET in HCC have...

Original Article

April 11, 2025

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, et al.

Clin Mol Hepatol. 2025;31(3):1058-1070.

Background/Aims: Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in...

Original Article

April 21, 2025

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study

Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, et al.

Clin Mol Hepatol. 2025;31(3):1071-1083.

Background/Aims: Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type...

Original Article

April 23, 2025

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study

Xianhua Mao, Xinrong Zhang, Rongtao Lai, et al.

Clin Mol Hepatol. 2025;31(3):1084-1099.

Background/Aims: Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease...

Current Issue: Volume 31(3); Jul 2025

This archive contains links to the full-text of all issues of Clin Mol Hepatol.

Current issue

Volume 31(3); July

All issues

Vol. 31
2025

v.31(1)
Jan 2025

v.31(Suppl)
Feb 2025

v.31(2)
Apr 2025

v.31(3)
Jul 2025

Vol. 30
2024

v.30(1)
Jan 2024

v.30(2)
Apr 2024

v.30(3)
Jul 2024

v.30(Suppl)
Sep 2024

v.30(4)
Oct 2024

Vol. 29
2023

v.29(1)
Jan 2023

v.29(Suppl)
Feb 2023

v.29(2)
Apr 2023

v.29(3)
Jul 2023

v.29(4)
Oct 2023

Vol. 28
2022

v.28(1)
Jan 2022

v.28(2)
Apr 2022

v.28(3)
Jul 2022

v.28(4)
Oct 2022

Vol. 27
2021

v.27(1)
Jan 2021

v.27(2)
Apr 2021

v.27(3)
Jul 2021

v.27(4)
Oct 2021

Vol. 26
2020

v.26(1)
Jan 2020

v.26(2)
Apr 2020

v.26(3)
Jul 2020

v.26(4)
Oct 2020

Vol. 25
2019

v.25(1)
Mar 2019

v.25(2)
Jun 2019

v.25(3)
Sep 2019

v.25(4)
Dec 2019

Vol. 24
2018

v.24(1)
Mar 2018

v.24(2)
Jun 2018

v.24(3)
Sep 2018

v.24(4)
Dec 2018

Vol. 23
2017

v.23(1)
Mar 2017

v.23(2)
Jun 2017

v.23(3)
Sep 2017

v.23(4)
Dec 2017

Vol. 22
2016

v.22(1)
Mar 2016

v.22(2)
Jun 2016

v.22(3)
Sep 2016

v.22(4)
Dec 2016

Vol. 21
2015

v.21(1)
Mar 2015

v.21(2)
Jun 2015

v.21(3)
Sep 2015

v.21(4)
Dec 2015

Vol. 20
2014

v.20(1)
Mar 2014

v.20(2)
Jun 2014

v.20(3)
Sep 2014

v.20(4)
Dec 2014

Vol. 19
2013

v.19(1)
Mar 2013

v.19(2)
Jun 2013

v.19(3)
Sep 2013

v.19(4)
Dec 2013

The Korean Journal of Hepatology1995 (Vol.1 No.1) to 2012 (Vol.18 No.1)

Vol. 18
2012

v.18(1)
Mar 2012

v.18(2)
Jun 2012

v.18(3)
Sep 2012

v.18(4)
Dec 2012

Vol. 17
2011

v.17(1)
Mar 2011

v.17(2)
Jun 2011

v.17(3)
Sep 2011

v.17(4)
Dec 2011

Vol. 16
2010

v.16(1)
Mar 2010

v.16(2)
Jun 2010

v.16(3)
Sep 2010

v.16(4)
Dec 2010

Vol. 15
2009

v.15(1)
Mar 2009

v.15(2)
Jun 2009

v.15(3)
Sep 2009

v.15(4)
Dec 2009

v.15(60)
Dec 2009

Vol. 14
2008

v.14(1)
Mar 2008

v.14(2)
Jun 2008

v.14(3)
Sep 2008

v.14(4)
Dec 2008

Vol. 13
2007

v.13(1)
Mar 2007

v.13(2)
Jun 2007

v.13(3)
Sep 2007

v.13(4)
Dec 2007

Vol. 12
2006

v.12(1)
Mar 2006

v.12(2)
Jun 2006

v.12(3)
Sep 2006

v.12(4)
Dec 2006

Vol. 11
2005

v.11(1)
Mar 2005

v.11(2)
Jun 2005

v.11(3)
Sep 2005

v.11(4)
Dec 2005

Vol. 10
2004

v.10(1)
Mar 2004

v.10(2)
Jun 2004

v.10(3)
Sep 2004

v.10(4)
Dec 2004

Vol. 9
2003

v.9(1)
Mar 2003

v.9(2)
Jun 2003

v.9(3)
Sep 2003

v.9(4)
Dec 2003

Vol. 8
2002

v.8(1)
Mar 2002

v.8(2)
Jun 2002

v.8(3)
Sep 2002

v.8(4)
Dec 2002

Vol. 7
2001

v.7(1)
Mar 2001

v.7(2)
Jun 2001

v.7(3)
Sep 2001

v.7(4)
Dec 2001

Vol. 6
2000

v.6(1)
Mar 2000

v.6(2)
Jun 2000

v.6(3)
Sep 2000

v.6(4)
Dec 2000

Vol. 5
1999

v.5(1)
Mar 1999

v.5(2)
Jun 1999

v.5(3)
Sep 1999

v.5(4)
Dec 1999

Vol. 4
1998

v.4(1)
Mar 1998

v.4(2)
Jun 1998

v.4(3)
Sep 1998

v.4(4)
Dec 1998

Vol. 3
1997

v.3(1)
Mar 1997

v.3(2)
Jun 1997

v.3(3)
Sep 1997

v.3(4)
Dec 1997

Vol. 2
1996

v.2(1)
Jun 1996

v.2(2)
Dec 1996

Vol. 1
1995

v.1(1)
Jun 1995

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 12523	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7621	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7103	MAFLD: How is it different from NAFLD?
Viewed By 5676	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5560	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis